Moderna

Moderna, founded in 2010, is a pioneer in mRNA medicine, fundamentally reshaping how vaccines and therapeutics are created and delivered. By blending advanced scientific innovation with a proprietary technology platform, the company addresses complex challenges across infectious diseases, oncology, rare disorders, and autoimmune conditions. Their commitment to improving human health is supported by a global team dedicated to developing mRNA-based medicines that provide lasting clinical impact. Learn about Moderna's global headquarters for comprehensive details on their primary operational hub located in Cambridge, Massachusetts.

Operating with a workforce of 1,000-5,000 employees, Moderna maintains a highly active clinical-stage pipeline. The organization leverages its end-to-end manufacturing capabilities and contract development services to accelerate the transition from discovery to commercial-stage production. Their operational strategy focuses on scaling synthetic biology and data-driven drug development to meet global demand. Meet Moderna's team to gain insights into the leadership and scientific experts driving their organizational structure and ongoing research initiatives.

Moderna (NASDAQ: MRNA) maintains a strong market position within the pharmaceutical and healthcare sectors, reporting annual revenue of $2.2B. The company has successfully secured substantial capital through diverse funding channels, including strategic corporate investments from industry partners and critical grants from organizations like BARDA and DARPA. This financial stability supports their extensive development programs and long-term growth strategy. Explore financial highlights to review detailed metrics, fiscal performance, and their current capital structure.